The 1 September 2014 issue of the Schedule of Pharmaceutical Benefits is now available.  The Schedule contains a number of new and revised listings:

• Certolizumab pegol (Cimzia) - new indication
• Everolimus (Afinitor) - new indication
• Ranibizumab (Lucentis) - new formulation
• Macitentan (Opsumit) - new listing

For more details, go to: http://www.pbs.gov.au/browse/changes